187 related articles for article (PubMed ID: 30636931)
1. Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target.
Fernandez ML; Dawson A; Hoenisch J; Kim H; Bamford S; Salamanca C; DiMattia G; Shepherd T; Cremona M; Hennessy B; Anderson S; Volik S; Collins CC; Huntsman DG; Carey MS
Cancer Cell Int; 2019; 19():10. PubMed ID: 30636931
[TBL] [Abstract][Full Text] [Related]
2. Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.
Fernández ML; DiMattia GE; Dawson A; Bamford S; Anderson S; Hennessy BT; Anglesio MS; Shepherd TG; Salamanca C; Hoenisch J; Tinker A; Huntsman DG; Carey MS
Am J Cancer Res; 2016; 6(10):2235-2251. PubMed ID: 27822414
[TBL] [Abstract][Full Text] [Related]
3. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
[TBL] [Abstract][Full Text] [Related]
4. NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.
Llaurado Fernandez M; Hijmans EM; Gennissen AMC; Wong NKY; Li S; Wisman GBA; Hamilton A; Hoenisch J; Dawson A; Lee CH; Bittner M; Kim H; DiMattia GE; Lok CAR; Lieftink C; Beijersbergen RL; de Jong S; Carey MS; Bernards R; Berns K
Mol Cancer Ther; 2022 Dec; 21(12):1862-1874. PubMed ID: 36198031
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Recurrent Low-grade Serous Ovarian Cancer With MEK Inhibitors: A Systematic Review.
Kulkarni A; Cooke C; Fazelzad R; Fung-Kee-Fung M; May T; Zigras T
Am J Clin Oncol; 2024 Jan; 47(1):11-16. PubMed ID: 37823720
[TBL] [Abstract][Full Text] [Related]
6. Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.
Napolitano S; Matrone N; Muddassir AL; Martini G; Sorokin A; De Falco V; Giunta EF; Ciardiello D; Martinelli E; Belli V; Furia M; Kopetz S; Morgillo F; Ciardiello F; Troiani T
J Exp Clin Cancer Res; 2019 Dec; 38(1):492. PubMed ID: 31842958
[TBL] [Abstract][Full Text] [Related]
7. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
[TBL] [Abstract][Full Text] [Related]
8. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
[TBL] [Abstract][Full Text] [Related]
9. MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.
Hew KE; Miller PC; El-Ashry D; Sun J; Besser AH; Ince TA; Gu M; Wei Z; Zhang G; Brafford P; Gao W; Lu Y; Mills GB; Slingerland JM; Simpkins F
Clin Cancer Res; 2016 Feb; 22(4):935-47. PubMed ID: 26482043
[TBL] [Abstract][Full Text] [Related]
10. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS
Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
[TBL] [Abstract][Full Text] [Related]
12. Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity.
Hong A; Piva M; Liu S; Hugo W; Lomeli SH; Zoete V; Randolph CE; Yang Z; Wang Y; Lee JJ; Lo SJ; Sun L; Vega-Crespo A; Garcia AJ; Shackelford DB; Dubinett SM; Scumpia PO; Byrum SD; Tackett AJ; Donahue TR; Michielin O; Holmen SL; Ribas A; Moriceau G; Lo RS
Cancer Discov; 2021 Mar; 11(3):714-735. PubMed ID: 33318037
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer.
Kurimchak AM; Shelton C; Herrera-Montávez C; Duncan KE; Chernoff J; Duncan JS
Mol Cancer Res; 2019 Aug; 17(8):1721-1734. PubMed ID: 31043489
[TBL] [Abstract][Full Text] [Related]
14. Ras Pathway Activation and MEKi Resistance Scores Predict the Efficiency of MEKi and SRCi Combination to Induce Apoptosis in Colorectal Cancer.
Davis TB; Gupta S; Yang M; Pflieger L; Rajan M; Wang H; Thota R; Yeatman TJ; Pledger WJ
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326598
[TBL] [Abstract][Full Text] [Related]
15. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
16. A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
O'Shea J; Cremona M; Morgan C; Milewska M; Holmes F; Espina V; Liotta L; O'Shaughnessy J; Toomey S; Madden SF; Carr A; Elster N; Hennessy BT; Eustace AJ
Oncotarget; 2017 Oct; 8(49):85120-85135. PubMed ID: 29156708
[TBL] [Abstract][Full Text] [Related]
17. Targeting SHP2 sensitizes differentiated thyroid carcinoma to the MEK inhibitor.
Zhi J; Yi J; Hou X; Wang W; Yang W; Hu L; Huang J; Guo S; Ruan X; Gao M; Zheng X
Am J Cancer Res; 2022; 12(1):247-264. PubMed ID: 35141016
[TBL] [Abstract][Full Text] [Related]
18. Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.
Brauswetter D; Gurbi B; Varga A; Várkondi E; Schwab R; Bánhegyi G; Fábián O; Kéri G; Vályi-Nagy I; Peták I
PLoS One; 2017; 12(9):e0185687. PubMed ID: 28957417
[TBL] [Abstract][Full Text] [Related]
19. MEK inhibitor resistance mechanisms and recent developments in combination trials.
Kun E; Tsang YTM; Ng CW; Gershenson DM; Wong KK
Cancer Treat Rev; 2021 Jan; 92():102137. PubMed ID: 33340965
[TBL] [Abstract][Full Text] [Related]
20. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]